Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
- Tuesday, February 21, 2023, 7:11
- Environment
- Add a comment
Phase 2 open-label study data reinforce donidalorsen’s potential to be a best-in-class prophylactic treatment for patients living with hereditary angioedema Ionis is preparing to launch donidalorsen, one of its three near-term commercial opportunities CARLSBAD, Calif., Feb. 21, 2023…
About the Author
adminasapcorp has written 41552 stories on this site.